We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug & Device Products
FDAnews Books Library
Events
Form 483s Database
Publications
Webinar Training Pass
eCFR and Guidances
Books
Clinical Products
Advertising
White Papers
Contact Us
About Us
COVID-19
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Liatte Krueger
Liatte Krueger
Products
PRODUCTS
PharmScript
Tonia Bernard
and
Liatte Krueger
Price:
$117.00
View
Elite Laboratories, Inc.
Jose M. Cayuela
,
Liatte Krueger
,
Melissa T. Roy
, and
Nancy F. Scheraga
Price:
$117.00
View
PETNET Solutions, Inc.
Michael R. Klapal
,
Liatte Krueger
, and
Melissa Ray
Price:
$117.00
View
Konsyl Pharmaceuticals, Inc.
Jonathan Chapman
and
Liatte Krueger
Price:
$117.00
View
Orion Corporation, Orion Pharma
Liatte Krueger
Price:
$117.00
View
Naturex, Inc.
Liatte Krueger
Price:
$117.00
View
Contract Coating, Inc.
Liatte Krueger
Price:
$117.00
View
Excellentia International, LLC
Liatte Krueger
Price:
$117.00
View
Dimensional Merchandising, Inc.
Liatte Krueger
Price:
$117.00
View
Hoffmann La Roche, Inc.
Douglas C. Kovacs
,
Liatte Krueger
, and
Melba T. Rivera
Price:
$117.00
View
Upcoming Events
13
Jul
FDA Ad and Promo Enforcement Trends: Past, Present and Future
27
Jul
Applying the Lessons of the Pandemic to Your Upcoming Trial
28
Jul
EU-MDR’s Growing Pains: Are You Current with the Latest Developments?
28
Jul
Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does
02
Aug
Medical Device Cybersecurity: Understand the Latest Developments
03
Aug
Pharmaceutical Process Validation: Best Practices for Success
Featured Products
FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485
Selecting and Implementing Electronic Document Management Systems in the EU
Featured Stories
FX Receives FDA Clearance for Its FX V135 Shoulder Arthroplasty Platform
FDA Recommends Modified COVID-19 Vaccine Boosters Adapted to Omicron BA.4 and BA.5 Subvariants
FDA Approves Foundation Medicine’s Companion Diagnostic for Genentech’s Rozlytrek
Novartis Pays $100 Million for Mallinckrodt’s Priority Review Voucher
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
